Literature DB >> 35908250

Latest research progress on anticancer effect of baicalin and its aglycone baicalein.

Lin Wang1, Ting Feng2, Zhilian Su3, Chao Pi3, Yumeng Wei4,5, Ling Zhao6,7.   

Abstract

Cancer, which is a leading cause of deaths around the world, is characterized by genetic mutations and epigenetic changes. Baicalin and its aglycone baicalein, the major bioactive flavones derived from the dried root of Scutellaria baicalensis Georigi, belong to flavonoid compounds. Many studies demonstrated that both of them exhibited remarkable promising anticancer activities. This study summarized potential anticancer mechanisms of baicalin and baicalein including induction of apoptosis, initiation of cell cycle arrest, suppression of metastasis, induction of autophagy, and regulation of immunity. Combination strategies involving baicalin or baicalein as chemotherapeutic adjuvants, clinical trial and safety were also discussed. In addition, we compared the difference in their anticancer effects. Interestingly, baicalein showed quicker and stronger inhibitory effects on multiple cancers than those of baicalin, probably due to its smaller size and high lipophilicity which contribute to fast absorption and improve ability to penetrate cells. Taken together, both baicalin and baicalein are effective in treating cancer with good tolerance. However, deglycosylation of baicalin to baicalein was found to have stronger anticancer potential.
© 2022. The Pharmaceutical Society of Korea.

Entities:  

Keywords:  Anticancer effect; Baicalein; Baicalin; Combination strategy; Mechanisms

Mesh:

Substances:

Year:  2022        PMID: 35908250     DOI: 10.1007/s12272-022-01397-z

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   6.010


  138 in total

1.  High doses of baicalin induces kidney injury and fibrosis through regulating TGF-β/Smad signaling pathway.

Authors:  Yi Cai; Wanqing Ma; Yichuan Xiao; Bo Wu; Xiaobing Li; Fengrong Liu; Jianhua Qiu; Genshui Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2017-08-10       Impact factor: 4.219

Review 2.  PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.

Authors:  Ali S Alzahrani
Journal:  Semin Cancer Biol       Date:  2019-07-16       Impact factor: 15.707

3.  Baicalein, a Natural Anti-Cancer Compound, Alters MicroRNA Expression Profiles in Bel-7402 Human Hepatocellular Carcinoma Cells.

Authors:  Beibei Bie; Jin Sun; Jun Li; Ying Guo; Wei Jiang; Chen Huang; Jun Yang; Zongfang Li
Journal:  Cell Physiol Biochem       Date:  2017-03-24

4.  The anti-metastatic effect of baicalein on colorectal cancer.

Authors:  Yuxia Chai; Jizhong Xu; Baojun Yan
Journal:  Oncol Rep       Date:  2017-02-10       Impact factor: 3.906

Review 5.  The potential applications of traditional Chinese medicine in Parkinson's disease: A new opportunity.

Authors:  Jiaxue Chen; Jingke Xu; Ping Huang; Yining Luo; Yuanshu Shi; Ping Ma
Journal:  Biomed Pharmacother       Date:  2022-03-31       Impact factor: 6.529

Review 6.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

Review 7.  Cancer and the Immune System: The History and Background of Immunotherapy.

Authors:  Maura Abbott; Yelena Ustoyev
Journal:  Semin Oncol Nurs       Date:  2019-09-13       Impact factor: 2.315

8.  Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer.

Authors:  Jia Chen; Cheng-Bo Yuan; Bo Yang; Xuan Zhou
Journal:  J Oncol       Date:  2021-11-25       Impact factor: 4.375

9.  Baicalein is a novel TLR4-targeting therapeutics agent that inhibits TLR4/HIF-1α/VEGF signaling pathway in colorectal cancer.

Authors:  Minting Chen; Keying Zhong; Jincheng Tan; Mingjing Meng; Chok Mei Liu; Baisen Chen; Chunhua Huang; Hoi Leong Xavier Wong; Zhaoxiang Bian; Tao Su; Hiu Yee Kwan
Journal:  Clin Transl Med       Date:  2021-11

10.  Inhibitory effect of baicalin and baicalein on ovarian cancer cells.

Authors:  Jianchu Chen; Zhaoliang Li; Allen Y Chen; Xingqian Ye; Haitao Luo; Gary O Rankin; Yi Charlie Chen
Journal:  Int J Mol Sci       Date:  2013-03-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.